{"title":"一例接受西妥昔单抗治疗的转移性癌症患者的对称性药物相关原发性和弯曲性发疹和痤疮样出疹","authors":"R. Coppola, B. Santo, S. Silipigni, V. Panasiti","doi":"10.4103/ccij.ccij_11_21","DOIUrl":null,"url":null,"abstract":"Over recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent or metastatic malignancy. We reported the case of a 74 year-old male patient with metastatic colorectal cancer who developed an SDRIFE and acneiform eruption during molecular target therapy with cetuximab and FOLFOX.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Symmetrical drug-related intertriginous and flexural exanthema and acneiform eruption in a patient with metastatic colorectal cancer treated with cetuximab\",\"authors\":\"R. Coppola, B. Santo, S. Silipigni, V. Panasiti\",\"doi\":\"10.4103/ccij.ccij_11_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Over recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent or metastatic malignancy. We reported the case of a 74 year-old male patient with metastatic colorectal cancer who developed an SDRIFE and acneiform eruption during molecular target therapy with cetuximab and FOLFOX.\",\"PeriodicalId\":44457,\"journal\":{\"name\":\"Clinical Cancer Investigation Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Investigation Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ccij.ccij_11_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Investigation Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ccij.ccij_11_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Symmetrical drug-related intertriginous and flexural exanthema and acneiform eruption in a patient with metastatic colorectal cancer treated with cetuximab
Over recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent or metastatic malignancy. We reported the case of a 74 year-old male patient with metastatic colorectal cancer who developed an SDRIFE and acneiform eruption during molecular target therapy with cetuximab and FOLFOX.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
